Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and
Yong Wang1, Chunyue Xu1, Yiqing Jiang1
1School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P.R. China.
Abstract:
Wee1 is a kinase that regulates cell cycle arrest in response to DNA damage. Wee1 inhibition is a potential strategy to suppress the growth of tumors with defective p53 or DNA repair pathways. However, the development of Wee1 inhibitors faces some challenges. AZD1775, the first-in-class Wee1 inhibitor, has poor kinase selectivity and dose-limiting toxicity. Here, we report the discovery of 12h, a highly selective and potent Wee1 inhibitor with a favorable pharmacokinetic profile. 12h showed strong antiproliferative effects against Lovo cells, a colorectal cancer cell line, both in vitro and in vivo. Moreover, 12h showed a clean kinase profile and effectively induced cell apoptosis. Our results suggest that 12h is a promising drug candidate for further development as a novel anticancer agent.
Insights
A new Wee1 inhibitor, 12h, shows potent and selective anticancer activity. This promising drug candidate effectively suppressed tumor growth in preclinical models and warrants further investigation for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Wee1 kinase regulates cell cycle arrest, making it a target for cancer therapy, especially in tumors with p53 or DNA repair defects.
- Existing Wee1 inhibitors like AZD1775 face challenges with selectivity and toxicity.
Purpose of the Study:
- To discover and characterize novel, highly selective Wee1 inhibitors.
- To evaluate the anticancer potential of a new compound, 12h, in preclinical models.
Main Methods:
- Discovery of 12h, a novel Wee1 inhibitor.
- Assessment of 12h's kinase selectivity and pharmacokinetic profile.
- Evaluation of 12h's antiproliferative and pro-apoptotic effects on Lovo colorectal cancer cells in vitro and in vivo.
Main Results:
- 12h demonstrated high selectivity for Wee1 kinase.
- 12h exhibited potent antiproliferative effects against Lovo cells.
- 12h showed favorable pharmacokinetics and induced apoptosis in cancer cells.
Conclusions:
- 12h is a highly selective and potent Wee1 inhibitor with a favorable profile.
- 12h shows significant promise as a novel anticancer agent for further clinical development.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Drug Discovery: Overview